1-2 of 2
Mike W. Zuurman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Patient-Reported Outcomes (PROs) Among Patients With Steroid-Refractory or -Dependent Chronic Graft-vs-Host Disease (cGVHD) Randomized to Ruxolitinib (RUX) vs Best Available Therapy (BAT)

Stephanie Lee, Franco Locatelli, Francis A. Ayuk, Tsila Zuckerman, Kentaro Fukushima, Juan Carlos Vallejo Llamas, Joseph Pidala, Nada Hamad, Ivan S. Moiseev, Francesca Bonifazi, Shashikant Apte, Robert Zeiser, Valkal Bhatt, Maanasa Gowda, Jackie Han, Tommaso Stefanelli, Mike W. Zuurman, Takanori Teshima
Journal: Blood
Blood (2021) 138 (Supplement 1): 3909.
https://doi.org/10.1182/blood-2021-144576
Published: 2021
Journal Articles

Characteristics of High-Risk Polycythemia Vera Patients with Suboptimal Response to First-Line Therapy Who Switched to Ruxolitinib Vs Those Who Did Not Switch: Findings from PV-Switch, a Multinational, Retrospective Chart Review Study

Steffen Koschmieder, Clemens Schulte, Eyck von der Heyde, Lambert Busque, Françoise Boyer-Perrard, Timothy Devos, Francesco Passamonti, Mike W. Zuurman, Carole Paley, Geralyn Gilotti, Wendy Y. Cheng, Chi Gao, Mu Cheng, Melody Wu, Mei Sheng Duh, Claire N. Harrison
Journal: Blood
Blood (2021) 138 (Supplement 1): 3646.
https://doi.org/10.1182/blood-2021-148254
Published: 2021